Abstract
Background: Long noncoding RNAs (lncRNAs) are tumor-related regulators and have been found to be involved in the underlying molecular mechanisms of colorectal cancer (CRC). However, the role of lncRNA LINC00115 during CRC progression is not entirely elucidated.
Methods: The expression of LINC00115 was analyzed in paired CRC tissue samples and its clinical significance was evaluated. The biological effects on CRC cells proliferation, apoptosis, migration, invasion and PI3K/AKT/mTOR signaling were assessed by Cell Counting Kit-8 assay, Transwell assay, flow cytometry analysis and Western blot, respectively. The regulatory relationship between LINC00115 and miR-489-3p was determined by dual-luciferase reporter assays.
Results: LINC00115 was significantly overexpressed in CRC and its overexpression predicted poor outcome of the patients. Downregulation of LINC00115 markedly inhibited CRC cell proliferation, increased cell apoptosis, and suppressed cell migration and invasion. Moreover, downregulation of LINC00115 led to the inactivation of PI3K/AKT/mTOR signaling. Bioinformatics analysis identified miR-489-3p as a candidate target of LINC00115. Furthermore, we revealed an inverse correlation between LINC00115 and miR-489-3p in CRC tissues. miR-489-3p might directly target LINC00115 and downregulation of miR-489-3p could rescue the biological effects induced by the absence of LINC0015.
Conclusion: LINC00115 serves as an excellent oncogene of CRC metastasis, the deeper understanding of LINC00115/miR-489-3p axis might provide potential therapeutic targets for CRC metastasis.
Introduction
Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide, often due to late-stage diagnosis and metastasis. While traditional research focused on protein-coding genes, it is now understood that non-coding RNAs play a massive role in cancer progression. Long non-coding RNAs (lncRNAs), transcripts longer than 200 nucleotides that do not code for proteins, regulate gene expression through various mechanisms. This study investigates LINC00115, a specific lncRNA whose role in CRC was previously poorly understood. The authors sought to determine if LINC00115 could serve as a biomarker for patient prognosis and to map the molecular circuitry it uses to promote cancer.
Materials and Methods
The study employed a multi-disciplinary approach combining clinical data with molecular biology. The team examined 100 paired tissue samples (cancerous vs. adjacent healthy tissue) from CRC patients treated at Henan Oncology Hospital (2012–2014). Small interfering RNAs (siRNAs) were used to "knock down" LINC00115 in CRC cell lines (LoVo and HT-29) to observe phenotypic changes. Standard functional assays, including CCK-8 (proliferation), Transwell (migration and invasion), and flow cytometry (apoptosis), were used to measure cell aggressiveness. Additionally, a dual-luciferase reporter assay confirmed the physical binding between LINC00115 and miR-489-3p, while Western blotting measured the activation of the PI3K/AKT/mTOR pathway.
Results
Clinical Significance and Prognostic Value
LINC00115 was significantly upregulated in 76% of CRC patient samples compared to normal tissue. High levels of LINC00115 were strongly associated with advanced T stage, lymph node metastasis (N stage), and advanced TNM stage (all $P < 0.001$).
Survival analysis indicated that patients with high LINC00115 expression experienced significantly shorter relapse-free survival. Multivariate Cox regression analysis further identified LINC00115 expression as an independent prognostic factor for CRC patients (HR = 2.479, $P = 0.014$).
Molecular Mechanism: The LINC00115/miR-489-3p/PI3K Axis
Functional experiments showed that reducing LINC00115 levels inhibited cell proliferation and invasion while increasing programmed cell death. Mechanistically, the study supports the "competing endogenous RNA" (ceRNA) hypothesis: LINC00115 acts as a molecular decoy, "sponging" up the tumor-suppressive microRNA miR-489-3p. This interaction prevents miR-489-3p from inhibiting its downstream targets, leading to the sustained activation of the PI3K/AKT/mTOR signaling pathway—a master switch for cell growth. The authors demonstrated a clear inverse correlation ($r = -0.494$) between LINC00115 and miR-489-3p in patient tissues, and showed that inhibiting miR-489-3p could "rescue" the oncogenic phenotype even after LINC00115 knockdown.
Discussion and Conclusion
This research identifies LINC00115 as a critical driver of CRC progression and metastasis. By sequestering miR-489-3p and activating the PI3K/AKT/mTOR pathway, LINC00115 promotes an aggressive cancer phenotype. While these in vitro findings are robust, future work using in vivo mouse models is necessary to confirm these mechanisms in a living system. Ultimately, LINC00115 represents both a reliable prognostic marker and a potential target for future RNA-based therapeutics in colorectal cancer.
Summary updated